Document is current

Article History

Received: 2 January 2021

Accepted: 13 January 2021

First Online: 2 February 2021

Ethics approval and consent to participate

: Data collection, analysis and preservation will be carried out according to established standards as good scientific practice, good clinical practice, guidelines and recommendations to ensure good epidemiological practice, and good practice of secondary analysis. The participation in the study is voluntary and has no influence on the further care of the patient. All patients will be informed in detail about the study contents and have to provide written consent. The risks of participation in this study for the patients are estimated to be very low for patients. Potentially occurring unexpected risks will be monitored regularly by scientific project management. The Ethics Committee of the Chamber of Physicians of the City Hamburg has approved this study. The trial is registered at ExternalRef removed (ExternalRef removed).

: Not applicable.

: LR, TS, CB, AE, MH, HS, and LK report no conflict of interest. CG reports personal fees from Amgen, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi Aventis, Abbott, and Prediction Biosciences outside the submitted work. GT reports receiving consulting fees from Acandis, grant support, and lecture fees from Bayer, lecture fees from Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo, and consulting fees and lecture fees from Stryker outside the submitted work. MR reports lecture and consulting fees from Bayer Vital, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, and Daiichi Sankyo outside the submitted work.